Intra-Cellular Therapies Inc (NASDAQ:ITCI) price on current trading day, rose 0.06% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $126.79.
A look at the stock’s price movement, the level at last check in today’s session was $126.71, moving within a range at $126.645 and $127.09. The beta value (5-Year monthly) was 0.973. Turning to its 52-week performance, $128.00 and $62.78 were the 52-week high and 52-week low respectively. Overall, ITCI moved 52.70% over the past month.
Intra-Cellular Therapies Inc’s market cap currently stands at around $13.47 billion, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 193.96M for the company’s revenue for the quarter, with a low and high estimate of 187.9M and 199.4M respectively. The average forecast suggests up to a 46.83% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 675.59M, representing a 45.49% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ITCI is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend ITCI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ITCI’s current price about 35.87% and 42.52% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 86.88, while 7-day volatility ratio is 3.57% and 3.07% in the 30-day chart. Further, Intra-Cellular Therapies Inc (ITCI) has a beta value of 0.67, and an average true range (ATR) of 4.45. Analysts have given the company’s stock an average 52-week price target of $103, forecast between a low of $79 and high of $132. Looking at the price targets, the low is 37.69% off recent price level in today’s trading while to achieve the yearly target high, it has to move -4.11%. Nonetheless, investors will most likely welcome a 18.76% jump to $103 which is the analysts’ median price.
If we refocus on Intra-Cellular Therapies Inc (NASDAQ:ITCI), historical trading data shows that trading volumes averaged 6.74 over the past 10 days and 1.56 million over the past 3 months. The company’s latest data on shares outstanding shows there are 106.00 million shares.
The 6.53% of Intra-Cellular Therapies Inc’s shares are in the hands of company insiders while institutional holders own 90.40% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.98 million on 2024-12-31, giving us a short ratio of 4.22. The data shows that as of 2024-12-31 short interest in Intra-Cellular Therapies Inc (ITCI) stood at 213.99999999999997 of shares outstanding, with shares short rising to 1.74 million registered in 2024-11-29. Current price change has pushed the stock 51.81% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ITCI stock continues to rise going into the next quarter.
